Isang magandang balita ngayon ang hatid ng US Medical team dahil umano sa isang successful na pag-attach ng isang kidney ng baboy sa isang tao, ito ay isang transplant breakthrough na tinatawag na “potential miracle.”

Ang surgery na ito ay sinimulan na noong September 25, na kung saan involve ang isang genetically modified donor animal at isang brain dead patient sa isang ventilator. Sa nasabing procedure, may permission naman ito sa pamilya na kung saan gumawa sila ng two-day experiment.

"It did what it's supposed to do, which is remove waste and make urine," Robert Montgomery, director of the transplant institute at New York University (NYU) Langone, sabi ng AFP sa isang interview.

Matapos ang nasabing proseso, nakuha umano ng organ (pig’s kidney) na i-reduce ang ang level ng molecule creatinine, isang key indicator ng kidney health na “elevated” sa patient bago ginawa ang transplant.

Si Montgomery ang nagsagawa ng surgery kasama ang ilan sa kanyang mga colleagues na isinagawa rin ng estimated 2 hours ang nasabing surgery.

Sinama nila ang kidney sa blood vessel sa ibabaw ng isa sa mga paa ng pasyente  para kanilang obserbahan ito at makuhanan ng mga biopsy samples. 

Ayon kay Montgomery, ang pasyente umano ay gusto talagang maging organ donor at ang kanyang pamilya ay na-disappoint umano noong sinabihan siya na ang organ ng kanilang loved ones ay hindi umano suitable para sa gagawing transplant. 

Ngunit, nakaramdam umano sila ng sense of relief na isa umano itong ibang opportunity for donation, sabi ni Montgomery. Ang pasyente ay inalis sa nasabing ventilator at nag “passed away” matapos ang 54-hour test.

'Important intermediate step'


Earlier research has shown that kidneys from pigs are viable in nonhuman primates for up to a year, but this was the first time it had been attempted with a human patient.

The donor pig belonged to a herd that had undergone a genetic editing procedure to knock out a gene that produces a particular sugar, which would otherwise have triggered a strong immune response and led to organ rejection.

The editing was performed by biotech firm Revivicor, a subsidiary of United Therapeutics.

"It is still a question what would happen three weeks from now, three months, three years," said Montgomery.

"The only way we're really going to be able to answer that is to move this into a living human trial. But I think this is a really important intermediate step, which tells us that at least initially, things are probably going to be okay."


He plans to submit the findings to a scientific journal in the next month, and says a clinical trial could take place in around a year or two.

The news was welcomed cautiously by outside experts, who nonetheless said they would like to see the peer-reviewed data before drawing firm conclusions.

"This news is a significant scientific achievement in the xenotransplantation field," Hynek Mergental, a surgeon at the University of Birmingham in Britain said in a statement.

Source: gmanetwork